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j ourna l homepage: www.e lsev ie r.com/ locate /bbad isHow does a medical doctor become a glycobiologistThe recent descriptions of novel disorders of glycosylation and the
increasing awareness for CDGs in the biomedical community are the
fruits seeded by committed scientists with a strong medical back-
ground and a profound knowledge of glycobiology. However, this
combination of skills and expertise is far from being obvious in the
current context of compartmentalized life sciences. Accordingly, we
will certainly not see glycobiology courses in the curriculumofmedical
students for a long time. Then, how does it happen that a medical
doctor becomes interested in glycobiology, while many mainstream
topics promise more research funding and celebrity? The recent
successes in CDG research certainly contribute to raising the medical
interest for this family of diseases. So, howabout thosemedical doctors
who fancied glycobiology at a timewhen no disorders of glycosylation
were known? Those early glycobiologists with a medical background
can be qualiﬁed as pioneers as they paved the way to the recent
achievements in CDG research. My good colleague Eric Berger
deﬁnitively belongs to these pioneers and his commitment to the
ﬁeld contributed to the discovery of many disorders of glycosylation.
Eric Berger’s interest for glycoconjugates was ﬁrst raised by the
work of Max Burger on the agglutination of cancer cells by lectins [1].
The idea that carbohydrate structures may affect the proliferation of
tumor cells was fascinating in many respects. Along this line, the work
of Georg Springer on the T-antigen in cancer was also of great
inspiration in those years [2]. Many reports focused on the role of
glycans as oncofetal antigens and the young ﬁeld of glycobiology was
busy at working out the mechanisms regulating the expression of
glycans in the context of cancer. A galactosyltransferase enzyme had
been claimed to be a reliable cancer marker [3] and galactosyltrans-
ferase activity was also involved in the regulation of the T-antigen [4].
Considering the importance of this activity in cancer, Eric Berger
decided to work toward the puriﬁcation of characterization of the
galactosyltransferase enzyme. In a masterpiece of protein chemistry,
the medical doctor succeeded at purifying the protein and at
generating antibodies to the galactosyltransferase. These antibodies
enabled the ﬁrst visualization of the Golgi apparatus by immunoﬂu-
orescence microscopy [5]. In addition, these antibodies have turned
out to be instrumental in many instances, such as in establishing the
localization of new intracellular proteins [6] and in determining the
cellular action of antibiotics such as monensin [7] and brefeldin-A [8].
Noteworthily, brefeldin-A is now used in a screening assay to detect
potential defects of glycosyltransferase trafﬁcking, such as those
encountered in deﬁciency of the COG complex.
The contribution of Eric Berger to the ﬁeld of medical glycobiology
is also evident when looking at his work on the Tn-syndrome, where
O-GalNAc is abnormally exposed on erythrocytes. Eric Berger
wondered whether a galactosyltransferase deﬁciency did account
for the abnormal exposure of the Tn-antigen. Indeed, the testing of
galactosyltransferase activity in the erythrocyte membrane of Tn-
syndrome patients conﬁrmed this hypothesis. With this experiment,
the ﬁrst disease of glycosylation was established [9].doi:10.1016/j.bbadis.2009.08.004As a colleague, I particularly enjoyed the discussionswith Eric Berger
around a cup of coffee. Besides learning a lot from his encyclopedic
knowledge of medicine and cell biology, I always took pleasure at our
attempts to rebuild the world of glycobiology. I remember one of these
discussions. When complaining that we glycobiologists are little
appreciated at our department of Physiology, Eric commented at
“what it does take to bring it to the next level.”Glycobiology has always
been and is still at many institutions a niche outside of the mainstream
interest. The conclusion of Eric was that the future of glycobiology may
be brighter if glycobiologists would join forces with other specialists,
like geneticists, clinical chemists, and especially with clinicians.
Fortunately, this discussion did not remain theoretical. Eric Berger
pushed hisﬁrst idea of a Europeannetwork dedicated to the research on
glycosylation disorders through his contacts to various European
groups. Thanks to Eric’s initial networking, clinicians and glycobiologists
across Europe were brought together, which ultimately led to the
characterizationofmultiple glycosylationdisordersover the last decade.
Eric Berger retired last summer from his faculty position. Typical
for Eric Berger, his farewell lecture was entitled “Perspectives of a
Second Fiddle,” which is a much too modest statement regarding his
achievement. Through his vision, perseverance, and diplomacy, Eric
has played a key role in CDG research. It is with great pleasure that I
join the other authors to dedicate the present issue of BBA to Eric
Berger, a medical doctor who became a glycobiologist. May his
example inspire many to follow!References
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